Abstract
Posttransplant lymphoproliferative disorder (PTLD) is an important and life-threatening complication of transplantation. Epstein-Barr virus (EBV) infections and use of potent immunosuppres¬sive agents are risk factors for the development of PTLD. The increase in the incidence of PTLD is accompanied by the development and availability of newer and potent immunosuppressors, such as anti-lymphocyte antibody (ALA) preparations. We report a case of renal transplantation with development of PTLD. Prior to development of the condition, the patient had received anti-thymocyte globulin (ATG) for the treatment of steroid-resistance rejection and used FK506 as a rescue agent for about seven months. ATG and FK506 were concurrently used for one week. The average serum concentration of FK506 was 11.32.5 ng/ml. The combined use of two potent immunosuppressors and excess blood level of FK506 are risk factors for PTLD.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
